Mf-1

Phase 1

UUniversity of Shizuoka

Mf-1 is one of 3 therapeutic programs targeting PARKINSON DISEASE (Disorder). It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

PARKINSON DISEASE (disorder)Recruiting

PARKINSON DISEASE (disorder)Phase 1

Recruiting

Competition

Competitive Landscape

2 competitors in PARKINSON DISEASE (disorder)

#DrugCompanyPhaseTrials

AB-1005

AAskBio Inc

Phase 2

1 2

Mf-1

UUniversity of Shizuoka

Phase 1

1 3

IRL757

IIntegrative Research Laboratories AB

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 1Recruiting

PARKINSON DISEASE (disorder)

NCT07666022

Clinical

Trials by Indication[1]

PARKINSON DISEASE (Disorder)1 trial

A Phase I Investigator-initiated First-in-human Study to Evaluate the Safety and Pharmacokinetics of MF1 in Healthy Adults and Patients With Parkinson's Disease (MF1-FIH)

Recruiting·UUniversity of Shizuoka·Phase 1·NCT07666022·58 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Mf-1. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Mf-1. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — University of Shizuoka company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: UUniversity of Shizuoka

Mf-1

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

PARKINSON DISEASE (Disorder)1 trial

References

Drug Info

Quick Facts

Related News